Baidu
map

CCLM:一种用于类固醇21-羟化酶的自体抗体检测的新型ELISA

2018-07-05 MedSci MedSci原创

本研究描述了针对类固醇21-羟化酶(21-OH Ab)的自身抗体的新型ELISA。在测定测试样品中,自身抗体在包被在板孔上的21-OH和液相21-OH-生物素之间形成桥接。通过添加链霉抗生物素蛋白过氧化物酶和色原性过氧化物酶底物检测与之结合的21-OH-生物素。 在对来自患有自身免疫性阿狄森氏病的患者的100个样品进行检测后,86个(86%)21-OH Ab ELISA阳性,而84个(84%

本研究描述了针对类固醇21-羟化酶(21-OH Ab)的自身抗体的新型ELISA。在测定测试样品中,自身抗体在包被在板孔上的21-OH和液相21-OH-生物素之间形成桥接。通过添加链霉抗生物素蛋白过氧化物酶和色原性过氧化物酶底物检测与之结合的21-OH-生物素。 在对来自患有自身免疫性阿狄森氏病的患者的100个样品进行检测后,86个(86%)21-OH Ab ELISA阳性,而84个(84%)在基于125 I标记的21-OH 的免疫沉淀测定中阳性。通过ELISA,928名健康成人献血者中,6名(0.6%)和49名1型糖尿病(T1DM)成年患者中的1名(2.0%)为阳性。来自格雷夫斯病(GD; n = 50),乳糜泻(n = 29),系统性红斑狼疮(n = 9)或类风湿性关节炎(n = 20)的成年患者的样品检测为阴性。然而,2/51(3.9%)GD患儿,3/69(4.3%)儿童患有桥本氏甲状腺炎(HT)和3/119(2.5%)患有单独T1DM或与自身免疫性甲状腺疾病相关的儿童均为ELISA阳性。 研究表明,新的检测方法可用于筛查已知患有临床自身免疫性艾迪生病的风险增加的患者,特别是患有

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1305139, encodeId=a4511305139a5, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313396, encodeId=8ebb131339603, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535773, encodeId=92231535e739a, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329770, encodeId=c469329e70c5, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jul 06 17:23:05 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2018-07-07 marongnuan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1305139, encodeId=a4511305139a5, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313396, encodeId=8ebb131339603, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535773, encodeId=92231535e739a, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329770, encodeId=c469329e70c5, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jul 06 17:23:05 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1305139, encodeId=a4511305139a5, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313396, encodeId=8ebb131339603, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535773, encodeId=92231535e739a, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329770, encodeId=c469329e70c5, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jul 06 17:23:05 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1305139, encodeId=a4511305139a5, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313396, encodeId=8ebb131339603, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535773, encodeId=92231535e739a, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Sat Jul 07 05:20:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329770, encodeId=c469329e70c5, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jul 06 17:23:05 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2018-07-06 1e0f8808m18(暂无匿称)

    好文章.学习了.

    0

相关资讯

CCLM:一种用于测定类固醇21-羟化酶自身抗体的新型ELISA

在本研究的化验样品中,自抗体在涂在厚板21-羟基和液相21-OH-biotin之间形成了一个桥接。研究人员通过添加过氧化物酶和显色过氧化物酶底物,以检测结合的21-OH-biotin。 结果显示,在100例自身免疫性Addison病患者的样本中,86例(86%)为21-OH Ab ELISA阳性,而在125i标记为21-OH的免疫沉淀试验中,84例(84%)为阳性。928例健康成人献血者中有6例

Baidu
map
Baidu
map
Baidu
map